Envestnet Asset Management Inc. Has $3.54 Million Stake in Haemonetics Corporation (NYSE:HAE)

Envestnet Asset Management Inc. boosted its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 16.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,746 shares of the medical instruments supplier's stock after acquiring an additional 7,678 shares during the period. Envestnet Asset Management Inc. owned 0.11% of Haemonetics worth $3,543,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. CWC Advisors LLC. grew its stake in Haemonetics by 7.4% during the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock worth $241,000 after buying an additional 212 shares during the last quarter. Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Haemonetics by 7.8% during the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 244 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the fourth quarter valued at approximately $25,000. Finally, KBC Group NV grew its stake in shares of Haemonetics by 19.9% during the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Trading Up 1.3%

NYSE:HAE opened at $75.19 on Friday. The firm's fifty day moving average is $72.13 and its 200-day moving average is $67.72. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62. Haemonetics Corporation has a 52 week low of $55.30 and a 52 week high of $94.99. The firm has a market cap of $3.61 billion, a P/E ratio of 22.72, a P/E/G ratio of 1.22 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The firm had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same quarter in the prior year, the business earned $0.90 earnings per share. The business's quarterly revenue was down 3.5% compared to the same quarter last year. Equities analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

HAE has been the topic of several research analyst reports. Raymond James Financial reissued a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Baird R W raised shares of Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Robert W. Baird began coverage on shares of Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. Needham & Company LLC reduced their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $95.00 price objective on shares of Haemonetics in a research note on Friday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.